Belle van Rosmalen

Company: Eli Lilly & Co.

Job title: Director - Incretin Outcomes

Seminars:

Overcoming Complex Pathophysiology & Patient Retention in Clinical Trials for GLP-1s to Treat MASH 1:30 pm - 2:00 pm

Discussing the benefits of placebo sharing strategies to overcome challenges in placebo arm requirements in clinical trials Outlining strategies for placebo patient retention when other GLP-1 trials are available Evaluating the use of real-world placebo patient databases to execute reliable time to event analysis Read more

day: Day One

Panel: Delving into Clinical Trial Design to Accurately Assess GLP-1s in Comorbidities of Obesity 3:00 pm - 3:30 pm

Exploring strategies for patient selection and stratification using baseline characteristics and specific comorbidities to assess differential treatment effects Considering the ethical implications of placebo arms to obtain reliable clinical data whilst ensuring patients receive required care Drawing on real world data to ensure adequate sample size and statistical testing to detect clinically meaningful differencesRead more

day: Day One